Can-Fite BioPharma CEO to Present Drug Developments at NobleCon21 on December 3
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 26 2025
0mins
Should l Buy CANF?
Source: Globenewswire
- Drug Development Update: Can-Fite BioPharma's CEO Motti Farbstein will present at NobleCon21 on December 3, detailing advancements in clinical trials for liver cancer, pancreatic cancer, and psoriasis, showcasing the company's innovative capabilities in biotechnology.
- Clinical Trial Phases: The company is currently conducting Phase III trials for liver cancer and psoriasis, along with a Phase IIa trial for pancreatic cancer, highlighting the diversity and potential market value of its drug development pipeline.
- Global Partnership Agreements: Can-Fite has established multiple global distribution agreements worth up to $455 million, including $130 million for pharmaceutical indications, indicating significant international market expansion potential.
- Investor Engagement: Farbstein will also hold one-on-one meetings with investors, enhancing communication between the company and its investors, thereby increasing market awareness and confidence in its development progress.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CANF?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CANF
About CANF
Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
UiPath to Join S&P Midcap 400 Index Effective January 2, 2026
- Market Focus: UiPath Inc. announced it will join the S&P Midcap 400 Index on January 2, 2026, replacing Synovus Financial Corp., a move expected to enhance the company's visibility and investor confidence.
- Stock Price Surge: Following this announcement, UiPath shares rose 6.8% to $17.05 in after-hours trading, reflecting market optimism regarding its future performance.
- FDA Approval: Agios Pharmaceuticals' AQVESME™ (mitapivat) received FDA approval for treating anemia in adults with alpha- or beta-thalassemia, although its stock fell 1.4%, this approval could pave the way for future sales growth.
- Stock Buyback Plan: Ramaco Resources announced a $100 million stock repurchase plan, with shares jumping 7.1% in after-hours trading, indicating the company's confidence in its value and potentially attracting more investor interest.
See More
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split, Shares Plunge 38.4%
- Reverse Stock Split Announcement: Aptevo Therapeutics has announced a 1-for-18 reverse stock split effective December 29, converting every 18 shares into one, which has led to a significant 38.4% drop in share price to $0.57, indicating a negative market reaction despite prior shareholder approval in July.
- Severe Market Reaction: Following the reverse stock split announcement, Aptevo's shares plummeted sharply during Friday's session, reflecting investor concerns about the company's future prospects, which could adversely affect its financing capabilities and market confidence.
- Shareholder Approval Context: The final ratio for the reverse split was approved by the board in mid-December, despite having received shareholder support at the July annual meeting, yet the market's response raises questions about the company's governance and strategic direction.
- Industry Impact: The sharp decline in Aptevo's stock price may affect its competitive position in the biopharmaceutical sector, particularly regarding financing and partnership opportunities, as investors may reassess its investment value.
See More
Can-Fite BioPharma Secures Patent in Brazil for A3AR Agonist in Sexual Dysfunction Treatment
- Patent Grant: Can-Fite BioPharma has secured a patent in Brazil for the use of A3 adenosine receptor agonists in treating sexual dysfunction, ensuring intellectual property protection in this market and enhancing the company's position in Latin America.
- Clinical Program Support: This patent reflects the company's broader clinical and preclinical programs, which are expected to pave the way for future partnering or commercialization opportunities in Latin America, further driving business growth.
- Market Reaction: Can-Fite's stock is trading at $0.24 in pre-market hours on the NYSE American, down 1.94% from the previous trading day, indicating a cautious market response to the news.
- Strategic Implications: Securing this patent not only provides Can-Fite with a competitive edge but may also attract potential investors and partners, helping the company establish a foothold in the rapidly evolving biopharmaceutical sector.
See More
Can-Fite Secures Brazilian Patent for Sexual Dysfunction Drug
- Patent Grant: Can-Fite BioPharma has been granted Patent No. BR112015002697-4 by the Brazilian Patent Office for the use of A3 adenosine receptor agonists in treating sexual dysfunction, further strengthening the company's global patent portfolio.
- Market Potential: Brazil, being one of the largest pharmaceutical markets in Latin America, presents significant business expansion opportunities for Can-Fite as demand for innovative sexual health therapies continues to grow.
- Therapeutic Mechanism Validation: Clinical and preclinical data from Can-Fite suggest that activation of the A3 adenosine receptor may modulate key signaling mechanisms related to erectile and sexual function, supporting the therapeutic rationale behind the patent.
- Strategic Opportunities: The patent not only validates the therapeutic versatility of A3 adenosine receptor agonists but also may create future partnering or commercialization opportunities for Can-Fite in Latin America.
See More
Can-Fite Secures Brazilian Patent for A3AR Agonist in Sexual Dysfunction Treatment
- Patent Grant: Can-Fite has secured Patent No. BR112015002697-4 in Brazil, protecting its A3 adenosine receptor agonists for treating sexual dysfunction, which further strengthens its global patent portfolio and indicates strategic positioning in the Latin American market.
- Market Potential: As one of the largest pharmaceutical markets in Latin America, Brazil's growing demand for innovative therapies in sexual health can be addressed by Can-Fite's patent, enhancing the company's competitive edge in this sector.
- Clinical Data Support: Preclinical and clinical data from Can-Fite suggest that activation of the A3 adenosine receptor may modulate key signaling mechanisms related to erectile and sexual function, supporting the therapeutic rationale for the patent and potentially paving the way for future commercialization opportunities.
- Strategic Development: The patent's grant not only validates the therapeutic versatility of A3 adenosine receptor agonists but also may create conditions for Can-Fite's partnership or commercialization opportunities in Latin America, further maximizing the value of its drug development platform.
See More
Multi Ways Holdings Reports 87.65% Revenue Growth to $26.44 Million in H1 2025
- Significant Revenue Growth: Multi Ways Holdings reported net revenue of $26.44 million for the first half of 2025, representing an impressive 87.65% increase from $14.09 million in the same period last year, indicating strong market demand and business expansion capabilities.
- Surge in Stock Price: Following the positive earnings report, the company's shares jumped 59.6% to $0.40 in pre-market trading, reflecting investor confidence in the company's future growth potential.
- Positive Market Reaction: The release of the financial results has significantly increased market attention on Multi Ways Holdings, which is expected to attract more investors to its future developments and strategic plans.
- Strategic Growth Outlook: The robust financial performance not only solidifies the company's position in the industry but also provides ample funding for future expansion and investments, potentially driving further increases in market share.
See More
UiPath to Join S&P Midcap 400 Index Effective January 2, 2026
- Market Focus: UiPath Inc. announced it will join the S&P Midcap 400 Index on January 2, 2026, replacing Synovus Financial Corp., a move expected to enhance the company's visibility and investor confidence.
- Stock Price Surge: Following this announcement, UiPath shares rose 6.8% to $17.05 in after-hours trading, reflecting market optimism regarding its future performance.
- FDA Approval: Agios Pharmaceuticals' AQVESME™ (mitapivat) received FDA approval for treating anemia in adults with alpha- or beta-thalassemia, although its stock fell 1.4%, this approval could pave the way for future sales growth.
- Stock Buyback Plan: Ramaco Resources announced a $100 million stock repurchase plan, with shares jumping 7.1% in after-hours trading, indicating the company's confidence in its value and potentially attracting more investor interest.
See More
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split, Shares Plunge 38.4%
- Reverse Stock Split Announcement: Aptevo Therapeutics has announced a 1-for-18 reverse stock split effective December 29, converting every 18 shares into one, which has led to a significant 38.4% drop in share price to $0.57, indicating a negative market reaction despite prior shareholder approval in July.
- Severe Market Reaction: Following the reverse stock split announcement, Aptevo's shares plummeted sharply during Friday's session, reflecting investor concerns about the company's future prospects, which could adversely affect its financing capabilities and market confidence.
- Shareholder Approval Context: The final ratio for the reverse split was approved by the board in mid-December, despite having received shareholder support at the July annual meeting, yet the market's response raises questions about the company's governance and strategic direction.
- Industry Impact: The sharp decline in Aptevo's stock price may affect its competitive position in the biopharmaceutical sector, particularly regarding financing and partnership opportunities, as investors may reassess its investment value.
See More
Can-Fite BioPharma Secures Patent in Brazil for A3AR Agonist in Sexual Dysfunction Treatment
- Patent Grant: Can-Fite BioPharma has secured a patent in Brazil for the use of A3 adenosine receptor agonists in treating sexual dysfunction, ensuring intellectual property protection in this market and enhancing the company's position in Latin America.
- Clinical Program Support: This patent reflects the company's broader clinical and preclinical programs, which are expected to pave the way for future partnering or commercialization opportunities in Latin America, further driving business growth.
- Market Reaction: Can-Fite's stock is trading at $0.24 in pre-market hours on the NYSE American, down 1.94% from the previous trading day, indicating a cautious market response to the news.
- Strategic Implications: Securing this patent not only provides Can-Fite with a competitive edge but may also attract potential investors and partners, helping the company establish a foothold in the rapidly evolving biopharmaceutical sector.
See More
Can-Fite Secures Brazilian Patent for Sexual Dysfunction Drug
- Patent Grant: Can-Fite BioPharma has been granted Patent No. BR112015002697-4 by the Brazilian Patent Office for the use of A3 adenosine receptor agonists in treating sexual dysfunction, further strengthening the company's global patent portfolio.
- Market Potential: Brazil, being one of the largest pharmaceutical markets in Latin America, presents significant business expansion opportunities for Can-Fite as demand for innovative sexual health therapies continues to grow.
- Therapeutic Mechanism Validation: Clinical and preclinical data from Can-Fite suggest that activation of the A3 adenosine receptor may modulate key signaling mechanisms related to erectile and sexual function, supporting the therapeutic rationale behind the patent.
- Strategic Opportunities: The patent not only validates the therapeutic versatility of A3 adenosine receptor agonists but also may create future partnering or commercialization opportunities for Can-Fite in Latin America.
See More
Can-Fite Secures Brazilian Patent for A3AR Agonist in Sexual Dysfunction Treatment
- Patent Grant: Can-Fite has secured Patent No. BR112015002697-4 in Brazil, protecting its A3 adenosine receptor agonists for treating sexual dysfunction, which further strengthens its global patent portfolio and indicates strategic positioning in the Latin American market.
- Market Potential: As one of the largest pharmaceutical markets in Latin America, Brazil's growing demand for innovative therapies in sexual health can be addressed by Can-Fite's patent, enhancing the company's competitive edge in this sector.
- Clinical Data Support: Preclinical and clinical data from Can-Fite suggest that activation of the A3 adenosine receptor may modulate key signaling mechanisms related to erectile and sexual function, supporting the therapeutic rationale for the patent and potentially paving the way for future commercialization opportunities.
- Strategic Development: The patent's grant not only validates the therapeutic versatility of A3 adenosine receptor agonists but also may create conditions for Can-Fite's partnership or commercialization opportunities in Latin America, further maximizing the value of its drug development platform.
See More
Multi Ways Holdings Reports 87.65% Revenue Growth to $26.44 Million in H1 2025
- Significant Revenue Growth: Multi Ways Holdings reported net revenue of $26.44 million for the first half of 2025, representing an impressive 87.65% increase from $14.09 million in the same period last year, indicating strong market demand and business expansion capabilities.
- Surge in Stock Price: Following the positive earnings report, the company's shares jumped 59.6% to $0.40 in pre-market trading, reflecting investor confidence in the company's future growth potential.
- Positive Market Reaction: The release of the financial results has significantly increased market attention on Multi Ways Holdings, which is expected to attract more investors to its future developments and strategic plans.
- Strategic Growth Outlook: The robust financial performance not only solidifies the company's position in the industry but also provides ample funding for future expansion and investments, potentially driving further increases in market share.
See More
